366 related articles for article (PubMed ID: 11209008)
21. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
Stein EA
Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
[TBL] [Abstract][Full Text] [Related]
22. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.
Maltz HC; Balog DL; Cheigh JS
Ann Pharmacother; 1999 Nov; 33(11):1176-9. PubMed ID: 10573315
[TBL] [Abstract][Full Text] [Related]
23. Atorvastatin improves endothelial function in renal-transplant recipients.
Asberg A; Hartmann A; Fjeldså E; Holdaas H
Nephrol Dial Transplant; 2001 Sep; 16(9):1920-4. PubMed ID: 11522880
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of atorvastatin in heart transplant recipients.
Patel DN; Pagani FD; Koelling TM; Dyke DB; Baliga RR; Cody RJ; Lake KD; Aaronson KD
J Heart Lung Transplant; 2002 Feb; 21(2):204-10. PubMed ID: 11834348
[TBL] [Abstract][Full Text] [Related]
25. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
Capone D; Stanziale P; Gentile A; Imperatore P; Pellegrino T; Basile V
Am J Nephrol; 1999; 19(3):411-5. PubMed ID: 10393380
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
Ooi TC; Heinonen T; Alaupovic P; Davignon J; Leiter L; Lupien PJ; Sniderman AD; Tan MH; Tremblay G; Sorisky A; Shurzinske L; Black DM
Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1793-9. PubMed ID: 9327779
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
Jones PH; McKenney JM; Karalis DG; Downey J
Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
Aguilar-Salinas CA; Gómez-Pérez FJ; Posadas-Romero C; Vázquez-Chávez C; Meaney E; Gulías-Herrero A; Guillén LE; Alvarado Vega A; Mendoza Pérez E; Eduardo Romero-Nava L; Angélica Gómez-Díaz R; Salinas-Orozco S; Moguel R; Novoa G
Atherosclerosis; 2000 Oct; 152(2):489-96. PubMed ID: 10998478
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
Jafari M; Ebrahimi R; Ahmadi-Kashani M; Balian H; Bashir M
J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):123-6. PubMed ID: 12808485
[TBL] [Abstract][Full Text] [Related]
30. [Drug clinics. Drug of the month. Atorvastatin (Lipitor)].
Scheen AJ
Rev Med Liege; 1998 Jun; 53(6):374-7. PubMed ID: 9713220
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
[TBL] [Abstract][Full Text] [Related]
32. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
33. Lipid modifying action of atorvastatin in comparison to combination of atorvastatin and nicotinic acid in patients with ischaemic heart disease.
Santanu G; Suhrita P; Mookerjee S; Tania K; Mita S; Pramit G; Sharmila G; Miraj M; Debdutta M
Indian Heart J; 2011; 63(5):434-7. PubMed ID: 23550422
[TBL] [Abstract][Full Text] [Related]
34. Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study.
Ghayour-Mobarhan M; Lamb DJ; Vaidya N; Livingstone C; Wang T; Ferns GA
Angiology; 2005; 56(1):61-8. PubMed ID: 15678257
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes.
Canas JA; Ross JL; Taboada MV; Sikes KM; Damaso LC; Hossain J; Caulfield MP; Gidding SS; Mauras N
Pediatr Diabetes; 2015 Mar; 16(2):79-89. PubMed ID: 25418907
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
[TBL] [Abstract][Full Text] [Related]
39. Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.
Guillén D; Cofán F; Ros E; Millán O; Cofán M; Brunet M
Mol Diagn Ther; 2010 Dec; 14(6):357-66. PubMed ID: 21047146
[TBL] [Abstract][Full Text] [Related]
40. Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study.
Gupta M; Martineau P; Tran T; Després JP; Gaw A; de Teresa E; Farsang C; Gensini GF; Leiter LA; Blanco-Colio LM; Egido J; Langer A;
J Clin Pharmacol; 2012 Jun; 52(6):850-8. PubMed ID: 21610204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
